For personalized medicine, it's back to the future: Pazdur explains
This article was originally published in Scrip
Executive Summary
As drug research and development moves increasingly more in the direction of personalized medicine, the types of trials that will be conducted will be more reminiscent of those undertaken in the 1960s – single-arm studies with the focus on response rates – with areas like oncology traveling "back to the future," said Dr Richard Pazdur, director of the FDA's Office of Oncology and Hematology Products.